for the genetic risk prediction and prevention of coronary heart disease GENinCode Plc (AIM: GENI), the Oxford based predictive genetics company focused on the prevention of cardiovascular disease ...

Diamond Capture Associates, a woman-owned business specializing in enterprise technology consulting and large-scale government implementations, and Incode Technologies, a global leader in identity ...

appear to be affecting South Korea’s music industry, as events in China featuring groups with Japanese members have been either cancelled or revised. One such event was K-pop girl group Le Sserafim’s ...

Incode Technologies, the global leader in identity security and fraud prevention, today announced the launch of Deepsight, a breakthrough AI defense that detects and blocks deepfakes, injected virtual ...

The agreement covers the U.S., Europe, the Middle East, and the African region. CARDIO inCode-Score is a clinically validated, commercially available polygenic risk score (PRS) based on DNA extracted ...

(MENAFN- EIN Presswire) EINPresswire/ -- GENinCode US Inc the Irvine based predictive genetics company focused on the prevention of coronary heart disease (“CHD” or“Heart Disease”) and risk assessment ...

GENinCode Plc (AIM: GENI), the Oxford based predictive genetics company focused on the prevention of coronary heart disease ("CHD" or "Heart Disease") and risk assessment of ovarian cancer, announces ...

SAN FRANCISCO, December 02, 2025--(BUSINESS WIRE)--Incode Technologies, the global leader in identity security and fraud prevention, today announced the launch of Deepsight, a breakthrough AI defense ...

Validated by Purdue University, this breakthrough AI system protects enterprises from deepfakes, synthetic identities, and AI-generated fraud at scale SAN FRANCISCO, December 02, 2025--(BUSINESS WIRE) ...

Incode Technologies Inc., an identity verification platform, is in preliminary talks to raise between $150 million and $300 million from investors at a valuation of as much as $3 billion, according to ...

The study followed over 47,000 individuals of diverse ancestry for 14 years, analysing the relationship between low-density lipoprotein cholesterol (LDL-C) and polygenic risk for CHD. Participants ...